Sign in Subscribe
1 min read Executive Debrief

NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China

NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China

In this inaugural annual NRDL+ debrief, we comprehensively examined pivotal developments and trends across basic medical insurance schemes, the commercial health insurance sector, and the provider sector. These developments and trends have a significant impact on pricing and access to innovative medicines in China, making this debrief a must-read for anyone interested in the Chinese market.

Format and Length

In addition to a concise PowerPoint summary of recent key developments and their implications for manufacturers, each section in the Debrief includes an "additional reading" segment cataloging our exclusive in-depth analysis articles on relevant subjects.

In total, the inaugural annual executive debrief comprises 51 slides and 16 original deep-dive articles, providing a comprehensive understanding of the evolving landscape of innovative medicines in China.


Published by:

Kelly Ke

You might also like...

Dec
04
NHSA Strengthens Control Over Outpatient Spending

NHSA Strengthens Control Over Outpatient Spending

Effectively navigating these regulatory changes will have significant and lasting implications for drug manufacturers, particularly in shaping their pricing strategies, reimbursement models, and distribution channel approaches in China.
7 min read
Jun
26
China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years

China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years

Executive Summary City Commercial Health Insurance ("Huiminbao") has been rapidly advancing, focusing on protecting the entire population against
4 min read
Jun
19
Shanghai Pilots: Leading Value-Based and Risk-Sharing Reimbursement for Medical Consumables in China

Shanghai Pilots: Leading Value-Based and Risk-Sharing Reimbursement for Medical Consumables in China

Shanghai utilizes value-based pricing negotiations and performance-linked payments for medical consumable reimbursements, providing insights into the future direction of high-value medical consumable reimbursement under China's basic medical insurance.
7 min read
Jun
12
China's Commercial Health Insurance Formulary Development: Current State and Future Directions

China's Commercial Health Insurance Formulary Development: Current State and Future Directions

Executive Summary The commercial health insurance sector in China presents substantial opportunities for growth, with the development of commercial insurance
9 min read
May
29
Fostering Medical Innovation: How China's Social and Commercial Insurance Can Work Together

Fostering Medical Innovation: How China's Social and Commercial Insurance Can Work Together

A healthy innovation ecosystem for medicines in China requires effective integration between basic and commercial health insurance. Success hinges on stakeholders operating within China's social security framework and focusing first on tackling the low-hanging fruit.
5 min read